首页|Association between glucagon‐like peptide‐1 receptor agonists and biliary‐related diseases in patients with type 2 diabetes: A?nationwide cohort study
Association between glucagon‐like peptide‐1 receptor agonists and biliary‐related diseases in patients with type 2 diabetes: A?nationwide cohort study
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
NSTL
Wiley
Abstract Study Objective Clinical trials have suggested that glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) may be associated with a higher risk of biliary‐related diseases in patients with type 2 diabetes. Limited real‐world studies have examined the comparative biliary safety of GLP‐1RAs versus other antihyperglycemic drugs. We aimed to estimate the comparative risk of biliary‐related diseases between GLP‐1RAs and sodium glucose cotransporter 2 inhibitors (SGLT2is), which are indicated for patients with similar diabetes severity in Taiwan. Design Retrospective cohort study. Data Source Taiwan National Health Insurance Database during 2011 to 2018. Patients Patients with type 2 diabetes who initiated GLP‐1RAs or SGLT2is. Intervention GLP‐1RAs versus SGLT2is. Measurements and Main Results We used an on‐treatment approach to examine the effect of continuous use and an intention‐to‐treat approach to assess the effect of initiation of GLP‐1RAs versus SGLT2is. We used Coxregression models to estimate the hazard ratios (HRs) and 95% confidenceintervals (CIs) for the composite hospitalized biliary‐related diseases, including acute cholecystitis or cholecystectomy, choledocholithiasis, and acute cholangitis, after matching each GLP‐1RA initiator to up to 10 SGLT2iinitiators using propensity scores (PSs). Among 78,253 PS‐matched patients, GLP‐1RA use was associated with a numerically higher risk of biliary‐related diseases versus SGLT2i use in the on‐treatment analysis, with an HR of 1.20 (95% CI, 0.93–1.56) for the composite outcome, an HR of 1.22 (95% CI, 0.92–1.62) for acute cholecystitis or cholecystectomy, an HR of 1.20 (95% CI, 0.69–2.07) for choledocholithiasis, and an HR of 1.14 (95% CI,0.82–2.42) for acute cholangitis. The HRs were more pronounced in theintention‐to‐treat analysis (1.27 [95% CI, 1.05–1.53] for the composite outcome, 1.29 [95% CI, 1.04–1.58] foracute cholecystitis or cholecystectomy, 1.74 [95% CI, 1.23–2.46] for choledocholithiasis, and 1.31 [95% CI, 0.89–1.94] for acute cholangitis). The increased risk of the composite outcome associated with GLP‐1RAs was more evident in patients aged ?60 years, women, and 120 days after treatment initiation. Liraglutide, but not dulaglutide, was associated with an elevated risk. Conclusions GLP‐1RAs might be associated with an elevated risk of biliary‐related diseases compared to SGLT2is in Asian patients with type 2 diabetes.
NSTL
Wiley
